<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03575156</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2017/54</org_study_id>
    <nct_id>NCT03575156</nct_id>
  </id_info>
  <brief_title>Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis</brief_title>
  <acronym>MICROLUPS</acronym>
  <official_title>Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our study aims at defining the role of circulating microparticles in the physiopathology of&#xD;
      two rare auto-immune diseases: systemic lupus erythematosus (SLE) and systemic scleroderma&#xD;
      (SSc). Microparticles might have an prognostic and diagnostic interest as well as potential&#xD;
      for the discovery of new therapeutic strategies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic lupus erythematosus (SLE) and systemic scleroderma (SSc) are two rare and&#xD;
      potentially life-threatening auto-immune systemic diseases. There is an urgent need to&#xD;
      describe prognostic factors and to discover new therapeutic pathways. Microparticles (MPs)&#xD;
      are small extracellular vesicles formed from activated cells including endothelial cells and&#xD;
      platelets. Preliminary data from our lab indicate that these MPs might play a key role in SLE&#xD;
      and SSc physiopathology. In fact, MPs from patients with SLE aggregates with T regulator&#xD;
      lymphocytes (LTregs) and decrease their activity, thereby promoting auto-immunity. Some works&#xD;
      also indicate that MPs might cargo DNA to the immune system, also promoting auto-immunity.&#xD;
      The investigators hypothesized that MPs levels might be a prognostic factor in SLE and SSc&#xD;
      and that studying the molecular mechanisms involved could provide new therapeutic targets.&#xD;
&#xD;
      Our study will recruit 100 patients with SLE or SSc followed in Bordeaux University Hospital.&#xD;
      Among classical disease activity information, blood and urine samples will be collected at&#xD;
      each visit to study circulating microparticles. Fundamental research will be realized on&#xD;
      patients' sample to study molecular mechanisms involved.&#xD;
&#xD;
      Clinical and biological disease activity, treatment and outcomes will be studied in&#xD;
      correlation with MPs to describe their potential prognostic role. Patients will be followed&#xD;
      at regular intervals as their usual follow-up would request. No extra visit will be needed&#xD;
      and blood samples will be drawn at the same times as those drawn for clinical purposes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in quantitative levels of circulating MPs between baseline and 12 months in the blood and urine samples of SLE and SSc patients</measure>
    <time_frame>At baseline (Day 0) and 12 months from baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease activity scores for SLE patients</measure>
    <time_frame>At baseline (Day 0) and 12 months from baseline</time_frame>
    <description>Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity scores for SSc patients</measure>
    <time_frame>At baseline (Day 0) and 12 months from baseline</time_frame>
    <description>Rodnan score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of P-selectin levels (soluble and on platelets) in the blood and urine samples of SLE and SSc patients</measure>
    <time_frame>At baseline (Day 0) and 12 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of FAS-ligand levels in the blood and urine samples of SLE and SSc</measure>
    <time_frame>At baseline (Day 0) and 12 months from baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Systemic Scleroderma</condition>
  <arm_group>
    <arm_group_label>Systemic lupus erythematosus (SLE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>systemic scleroderma (SSc)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation</description>
    <arm_group_label>Systemic lupus erythematosus (SLE)</arm_group_label>
    <arm_group_label>systemic scleroderma (SSc)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>urine sample</intervention_name>
    <description>6 ml</description>
    <arm_group_label>Systemic lupus erythematosus (SLE)</arm_group_label>
    <arm_group_label>systemic scleroderma (SSc)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of systemic lupus erythematosus or systemic sclerosis;&#xD;
&#xD;
          -  age â‰¥ 18 years;&#xD;
&#xD;
          -  being affiliated to health insurance, willing to participate and to sign informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or breastfeeding women;&#xD;
&#xD;
          -  patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty&#xD;
             by a judicial or administrative decision, minors, persons of legal age who are the&#xD;
             object of a legal protection measure or unable to express their consent)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe RICHEZ, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Bordeaux - service de rhumatologie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>Systemic Scleroderma</keyword>
  <keyword>autoimmunity</keyword>
  <keyword>microparticles</keyword>
  <keyword>platelets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

